We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.56%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNXP icon
76
Tonix Pharmaceuticals
TNXP
$154M
– –
0
– –
TRVN
77
DELISTED
Trevena, Inc.
TRVN
$2.19M 0.02%
1,520
+148
+11% +$272K
GNMX
78
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.15M 0.02%
1,618,089
– –
ARGX icon
79
argenx
ARGX
$55.3B
$2.12M 0.02%
+100,000
New +$2.08M
VIRX
80
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2M 0.02%
21,190
– –
KPTI icon
81
Karyopharm Therapeutics
KPTI
$159M
$1.96M 0.02%
14,466
– –
TRIL
82
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.82M 0.02%
413,697
– –
DMTX
83
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.81M 0.02%
1,251,881
– –
RARE icon
84
Ultragenyx Pharmaceutical
RARE
$2.49B
$1.55M 0.01%
25,000
-25,000
-50% -$1.51M
MDWD icon
85
MediWound
MDWD
$186M
$1.54M 0.01%
32,286
– –
JUNO
86
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.5M 0.01%
50,000
– –
IMDZ
87
DELISTED
Immune Design Corp.
IMDZ
$1.45M 0.01%
148,937
– –
MCRB icon
88
Seres Therapeutics
MCRB
$45.9M
$1.41M 0.01%
6,250
– –
JNCE
89
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.4M 0.01%
100,000
– –
MYOK
90
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.31M 0.01%
100,000
– –
CLLS
91
Cellectis
CLLS
$289M
$1.29M 0.01%
50,000
– –
NVIV
92
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$1.08M 0.01%
21
– –
MDGL icon
93
Madrigal Pharmaceuticals
MDGL
$12.7B
$939K 0.01%
57,762
– –
INFI
94
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$911K 0.01%
580,400
– –
PTN
95
Palatin Technologies
PTN
$14.1M
$882K 0.01%
1,640
– –
XLRN
96
DELISTED
Acceleron Pharma
XLRN
$874K 0.01%
28,765
– –
AFMD
97
DELISTED
Affimed
AFMD
$820K 0.01%
40,000
– –
CRBP icon
98
Corbus Pharmaceuticals
CRBP
$168M
$820K 0.01%
4,338
– –
FLGT icon
99
Fulgent Genetics
FLGT
$566M
$799K 0.01%
125,000
– –
DVAX
100
DELISTED
Dynavax Technologies
DVAX
$724K 0.01%
75,000
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Baker Bros. Advisors held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Baker Bros. Advisors's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Baker Bros. Advisors fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Baker Bros. Advisors opened 6 new positions and closed 4 in Q2 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.